UBS Reiterates 10% Revenue Growth Forecast for Healthcare Sector in 2026, Names 3SBio (01530.HK) as Top Pick

According to the SmartCom APP, UBS released a research report stating that based on the latest industry sales data and licensing transaction status, it is currently forecasted that the healthcare companies rated by UBS will experience median revenue growth of 16% in 2025 and 10% in 2026. It is believed that the sales performance of core products for most companies will meet or exceed the bank's expectations.

UBS Replaces Hansoh Pharma (03692) with 3SBIOINC (01530) as Top Pick, Assigns "Buy" Rating and Target Price of HKD 41 to 3SBIOINC, Citing Reasonable Valuation. Looking Ahead to 2026, the Firm Forecasts a Median Revenue Growth of 10% for the Sector, Favoring Steady Sales Growth of Innovative Drugs and Promising R&D Progress.

The bank raised target prices for several stocks: CSPC (01093) from HKD 10 to HKD 10.9, Hansoh Pharma from HKD 48.2 to HKD 51.5, and Hengrui Pharma (01276) from HKD 96.9 to HKD 98.3, assigning ratings of "Neutral," "Buy," and "Buy" respectively.